Cardiovascular Journal of Africa: Vol 35 No 2 (MAY/AUGUST 2024)

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 35, No 2, May – August 2024 122 AFRICA 12.5 g three times weekly has been suggested.29,30 STS-induced metabolic acidosis might be solved by bicarbonate dialysate. Finally, the negative impact on bone integrity deserves further research.55 To the best of our knowledge, hypercalcaemia after treatment with intravenous STS has been described in only one study.56 This aspect is worthy of further study. The endpoints of the included studies seemed weak and lacked a comparison of death rates. Outcomes for intravenous STS in calciphylaxis are available. Treatment of uraemic calciphylaxis with systemic STS has been reported to have a significantly lower overall mortality rate than conventional treatment.56,57 However, a meta-analysis analysed the pooled mortality rate resulting from seven included cohort studies on the use of intravenous STS, which was not different in patients who received STS compared with the control group.58 Large-scale prospective studies are needed to validate the effect of sodium thiosulfate on long-term survival in dialysis patients. Limitations This study aimed to determine the effect of intravenous STS on vascular calcification, which is very meaningful and has clinical value. Unfortunately, only eight studies were included. This metaanalysis had several limitations that should be confirmed. First, the article has limitations primarily due to the quality of the studies and the size of the data. But we believe the article in its current version has useful information for clinicians and researchers. Second, vascular calcification is a slowly progressing process, and it takes a long time to observe the effect on the progression of vascular calcification. Due to the short duration (only three to 12 months) of the eight included studies, the long-term actions of intravenous STS treatment are still unclear. Finally, there is no information on whether the decrease in these scores is sustained after STS is stopped or whether the reduction affects outcomes. Conclusion This meta-analysis suggested that intravenous STS may be a promising agent to slow down vascular calcification and arterial stiffness in dialysis patients with end-stage renal disease. Given the low cost of STS and its acceptable rate of adverse effects, it should be considered when developing healthcare policies for dialysis patients. Further studies including longer follow-up times are warranted to evaluate STS effectiveness and safety and to understand the mechanisms in treating dialysis patients with vascular calcification. This study received financial support from the Scientific Research Fund of Aerospace Center Hospital (YN202209) and the Natural Science Foundation of China (NSFC) (82170686). References 1. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 2008; 23(2): 586–593. 2. Tsai CH, Lin LY, Lin YH, Tsai IJ, Huang JW. Abdominal aorta calcification predicts cardiovascular but not non-cardiovascular outcome in patients receiving peritoneal dialysis: A prospective cohort study. Medicine 2020; 99(37): e21730. 3. Prati F, Biccirè FG, Budassi S. Present and future of coronary risk assessment. Eur Heart J Suppl 2021; 8(23, Suppl E): E123–E127. 4. Wen W, Portales-Castillo I, Seethapathy R, Krinsky S, Kroshinsky D, Kalim S, Goverman J, Nazarian RM, Chitalia V, Malhotra R, Kramann R, Malhotra CK, Nigwekar SU. Intravenous sodium thiosulphate for vascular calcification of hemodialysis patients-a systematic review and meta-analysis. Nephrol Dial Transplant 2023; 38(3): 733–745. 5. Andrews J, Psaltis PJ, Bartolo BAD, Nicholls SJ, Puri R. Coronary arterial calcification: A review of mechanisms, promoters and imaging. Trends Cardiovasc Med 2018; 28(8): 491–501. 6. Nuotio K, Koskinen SM, Mäkitie L, Tuimala J, Ijäs P, Heikkilä HM, et al. Warfarin treatment is associated to increased internal carotid artery calcification. Front Neurol 2021; 12(12): 696244. 7. Xu JP, Zeng RX, Liao PD, Zhang MZ. Effect of lanthanum carbonate on the progression of coronary artery calcification in hemodialysis patients: A meta-analysis of randomized controlled trials. Hemodial Int 2021; 13. Epub ahead of print. 8. Hildebrand S, Cunningham J. Is there a role for bisphosphonates in vascular calcification in chronic kidney disease? Bone 2021; 142: 115751. 9. Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med 2004; 164(12): 1285–1292. 10. Niu Q, Hong Y, Lee CH, Men C, Zhao H, Zuo L. Abdominal aortic calcification can predict all-cause mortality and CV events in dialysis patients: A systematic review and meta-analysis. PLoS One 2018; 13(9): e0204526.. 11. Kollias A, Kyriakoulis KG, Gravvani A, Anagnostopoulos I, Stergiou GS. Automated pulse wave velocity assessment using a professional oscillometric office blood pressure monitor. J Clin Hypertens 2020; 22(10): 1817–1823. 12. Zhang Q, Yin K, Zhu M, Lin X, Fang Y, Lu J, et al. Combining pulse wave velocity with galectin-3 to predict mortality and cerebrovascular and cardiovascular events in hemodialysis patients. Front Med 2020; 20(7): 579021. 13. Kakani E, Elyamny M, Ayach T, El-Husseini A. Pathogenesis and management of vascular calcification in CKD and dialysis patients. Semin Dial 2019; 32(6): 553–561. 14. Singh A, Tandon S, Tandon C. An update on vascular calcification and potential therapeutics. Mol Biol Rep 2021; 48(1): 887–896. 15. Matuszek G, Cushman M, Benjamin EJ, Kritchevsky SB, Weiner DE. Vitamin K status, cardiovascular disease, and all-cause mortality: a participant-level meta-analysis of 3 US cohorts. Am J Clin Nutr 2020; 111(6): 1170–1177. 16. Lee M, McGeer EG, McGeer PL. Sodium thiosulfate attenuates glialmediated neuroinflammation in degenerative neurological diseases. J Neuroinflamm 2016; 13: 32. 17. Saito T, Mima Y, Sugiyama M, Miyazawa N, Iida A, Kanazawa N, et al. Multidisciplinary management of calciphylaxis: a series of 5 patients at a single facility. CEN Case Rep 2020; 9(2): 122–128. 18. Chen NC, Hsu CY, Chen CL. The strategy to prevent and regress the vascular calcification in dialysis patients. Biomed Res Int 2017; 2017: 9035193. 19. Piccoli GB, Torreggiani M, Gendrot L, Nielsen L. Setting the clock back: new hope for dialysis patients. Sodium thiosulphate and the regression of vascular calcifications. J Nephrol 2020; 16: 1–3. 20. Ramani R, Ramachandran A, Ravindran S, Kurian GA. Erythrocyte membrane bound atpase and antioxidant enzyme changes associated with vascular calcification is reduced by sodium thiosulfate. Indian J Clin Biochem 2017; 32(4): 487–492. 21. Zhu XH, Chen L, Li YY, Du CL, Zhang AL, Qiu BZ, et al. The influence of sodium thiosulfate on blood vessel calcification and heart function of maintenance hemodialysis patient. Chinese Foreign Med Res 2020; 18(30): 1–3. [Chinese].

RkJQdWJsaXNoZXIy NDIzNzc=